Orphan Reach is the result of 15 years of international trial experience which has started as QED Clinical Services and was initially established as a functional service provider for the pharmaceutical industry. QED quickly evolved into a niche CRO known for rescuing clinical studies from other CROs where patient recruitment and retention were the main challenges. Many of these projects have been conducted in smaller patient populations, particularly in rare diseases where larger service providers struggled to find the optimal development strategy.

Orphan Reach are in business to provide the biopharmaceutical industry with the ultimate product lifecycle solution including clinical support and integrated patient management.
The purpose of Orphan Reach is to expedite the development of orphan drugs and facilitate patient access to treatments which can improve the quality of life of patients and their families. By driving best practice our team can provide continued, seamless, high quality support to biopharmaceutical companies throughout any stage of the orphan product lifecycle, a service that has not previously been available.


16 November 2020